Serum C-reactive protein level predicts clinical outcomes in patients with non-small cell lung cancer harboring EGFR mutations.

Serum C-reactive protein level predicts clinical outcomes in patients with non-small cell lung cancer harboring EGFR mutations. Cancer Invest. 2020 Jan 27;:1-26 Authors: Koyama N, Aoshiba K, Nakamura H Abstract The aim of this study was to assess the association of serum C-reactive protein (CRP) levels with outcomes in 81 patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Patients with high serum CRP levels had lower therapeutic responses to EGFR-tyrosine kinase inhibitors (43.8%), and shorter time to treatment failure (TTF; 5.8 months) and overall survival (OS; 14.2 months) than those with low CRP levels. In multivariate analysis, serum CRP level was associated with TTF (hazard ratio [HR] 4.86) and OS (HR 49.42). High serum CRP levels may predict poor outcomes in patients with EGFR-mutated NSCLC. PMID: 31985315 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research